Showing results (281-290 of 451) with videos related to
Sort By:
Pageof 46
Nature Communications|April 6, 2022
Identification of host-pathogen-disease relationships using a scalable multiplex serology platform in UK BiobankAlexander J Mentzer, Nicole Brenner, Naomi Allen, et al.European Journal of Human Genetics : EJHG|November 30, 2006
Multiple QTL influence the serum Lp(a) concentration: a genome-wide linkage screen in the PROCARDIS studySimona Barlera, Claudia Specchia, Martin Farrall, et al.Critical Reviews in Clinical Laboratory Sciences|June 10, 2024
Methods applied to neonatal dried blood spot samples for secondary research purposes: a scoping reviewJordan Canning, Rona J Strawbridge, Zosia Miedzybrodzka, et al.JAMA|November 12, 2009
Major lipids, apolipoproteins, and risk of vascular disease, Emanuele Di Angelantonio, Nadeem Sarwar, et al.Journal of Neurosurgery|September 24, 2005
Preoperative and postoperative mapping of cerebrovascular reactivity in moyamoya disease by using blood oxygen level-dependent magnetic resonance imagingDavid J Mikulis, Gregory Krolczyk, Hubert Desal, et al.International Journal of Epidemiology|September 24, 2013
Exhaled carbon monoxide and its associations with smoking, indoor household air pollution and chronic respiratory diseases among 512,000 Chinese adultsQiuli Zhang, Liming Li, Margaret Smith, et al.Lancet (London, England)|April 11, 2003
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialPeter S Sever, Björn Dahlöf, Neil R Poulter, et al.European Journal of Preventive Cardiology|January 28, 2017
Burden of carotid artery atherosclerosis in Chinese adults: Implications for future risk of cardiovascular diseasesRobert Clarke, Huaidong Du, Om Kurmi, et al.Drugs|March 16, 2005
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialPeter S Sever, Björn Dahlöf, Neil R Poulter, et al.Diabetes Care|April 28, 2005
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA)Peter S Sever, Neil R Poulter, Björn Dahlöf, et al.Pageof 46